gip glp 1 drugs Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Free Comparison Chart: GLP-1 and
Description
Neuromolecular Med
10.1111/dom.14922 11 OvergaardR
de Vries, J.F.E
Butyrate administered in pharmacological doses (5 mM) directly to ex vivo rat islets can increase GSIS (Wang et al., 2022), but this effect might potentially be due to mechanisms unrelated to its binding to FFARs, such as on chromatin remodelling (Priyadarshini et al., 2015), found that primary isolated wild-type mouse islets secrete 50% more insulin in a GSIS assay following co-stimulation with acetate and Exendin-4 compared to FFA2 KO islets
danuglipron and lotiglipron were discontinued in development due to hepatotoxicity signals, underscoring safety considerations unique to this drug class
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al
